News

NovellusDx and Primetech announce that Primetech will provide NovellusDx' functional genomics assay "FACT – Functional Annotation for Cancer Treatment" as an exclusive dealer in Japan…
Read More...

The European Commission has granted marketing authorization for Cablivi (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic…
Read More...

Evox Therapeutics Ltd announces that it has raised £35.5 million ($45.4 million) of new capital in a Series B financing round. Redmile Group led the financing with significant new…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi (BAY94-9027, antihemophilic factor PEGylated-aucl) for the routine prophylactic treatment of…
Read More...

Tetraphase Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted approval of XERAVA (eravacycline) for the treatment of complicated intra-abdominal…
Read More...

PCI announced the completion of a purpose built -40°C storage and distribution facility at our North American Clinical Services Center of Excellence. The site, located in Rockford,…
Read More...

Evotec AG announced that CHDI Foundation, Inc. has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec.…
Read More...

Regen BioPharma has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear…
Read More...

CRF Health announced that its TrialMax Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study. The large-scale trial will involve up to…
Read More...

Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has appointed Arin Maercks as chief commercial…
Read More...

Alnylam Pharmaceuticals announced that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated…
Read More...

PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is…
Read More...

Pfizer Inc. announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety…
Read More...

Merck announced that the U.S. Food and Drug Administration (FDA) has approved two new HIV-1 medicines: DELSTRIGO, a once-daily fixed-dose combination tablet of doravirine (100 mg),…
Read More...

SunGen Pharma announced that it has entered into a Manufacturing Agreement with Grand River Aseptic Manufacturing to manufacture generic injectable pharmaceutical products. “We are…
Read More...

REGENXBIO Inc. announced that it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the…
Read More...

UPM Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO) focused on oral solid and semi-solid drug dosage forms, has appointed Dr. Chi-Chang Wung to the…
Read More...

Trovagene announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation…
Read More...

SGS announced it is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200m2 laboratory. The laboratory will be equipped with a number of…
Read More...

Sirona Biochem Corp. announced that it has received the $500,000 USD milestone payment from partner Wanbang Biopharmaceuticals Co., Ltd for approval by the China Food and Drug…
Read More...